Global Interferons Market 2019-2023
SKU ID : TNV-14770429 | Publishing Date : 08-Feb-2019 | No. of pages : 119
Detailed TOC of Global Interferons Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Interferon beta - Market size and forecast 2018-2023
• Interferon alfa - Market size and forecast 2018-2023
• Other interferons - Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Biogen
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Merck Sharp & Dohme Corp.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Interferon beta - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Interferon beta - Year-over-year growth 2019-2023 (%)
Exhibit 22: Interferon alfa - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Interferon alfa - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other interferons - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other interferons - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Prevalence of cancer types in the US
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Approved biosimilars
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Treatment costs of interferon therapeutics used for treatment of various diseases
Exhibit 48: Side effects of interferon therapeutics
Exhibit 49: Recently approved substitutes to interferons
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Some interferon biosimilars in market
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Bayer AG - Vendor overview
Exhibit 58: Bayer AG - Product segments
Exhibit 59: Bayer AG - Organizational developments
Exhibit 60: Bayer AG - Geographic focus
Exhibit 61: Bayer AG - Segment focus
Exhibit 62: Bayer AG - Key offerings
Exhibit 63: Bayer AG - Key customers
Exhibit 64: Biogen - Vendor overview
Exhibit 65: Biogen - Product segments
Exhibit 66: Biogen - Organizational developments
Exhibit 67: Biogen - Geographic focus
Exhibit 68: Biogen - Key offerings
Exhibit 69: Biogen - Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 77: Merck KGaA - Vendor overview
Exhibit 78: Merck KGaA - Business segments
Exhibit 79: Merck KGaA - Organizational developments
Exhibit 80: Merck KGaA - Geographic focus
Exhibit 81: Merck KGaA - Segment focus
Exhibit 82: Merck KGaA - Key offerings
Exhibit 83: Merck KGaA - Key customers
Exhibit 84: Merck Sharp & Dohme Corp. - Vendor overview
Exhibit 85: Merck Sharp & Dohme Corp. - Business segments
Exhibit 86: Merck Sharp & Dohme Corp. - Organizational developments
Exhibit 87: Merck Sharp & Dohme Corp. - Geographic focus
Exhibit 88: Merck Sharp & Dohme Corp. - Segment focus
Exhibit 89: Merck Sharp & Dohme Corp. - Key offerings
Exhibit 90: Merck Sharp & Dohme Corp. - Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: List of abbreviations
Keyplayers in Global Interferons Market 2019-2023
Bayer AGBiogen
F. Hoffmann-La Roche Ltd.
Merck KGaA
and Merck Sharp & Dohme Corp